Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 31 October 2019, 11:10 HKT/SGT
COPFL announced that its wholly-owned subsidiary-ZKO, has successfully completed a Phase II trial of Cyclosporine A Ophthalmic Gel

China, Oct 31, 2019 - (ACN Newswire) - China Ophthalmology Focus Limited ("COPFL") today announced that its wholly-owned subsidiary, Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Limited ("ZKO"), has successfully completed a Phase II trial of Cyclosporine A (CsA) Ophthalmic Gel in China ( registration No.:NCT03676335). Topline data show that the experimental drug has similar or a trend towards better efficacy than that of the marketed CsA Ophthalmic Emulsion.

The recently completed trial is a Phase II, randomised, single-blind, positive controlled, dose-finding study to assess the safety and efficacy of CsA Ophthalmic Gel in subjects with dry eye (Keratoconjunctivitis Sicca). The objective of the study is to explore and compare the efficacy and safety of CsA in a proprietary ophthalmic gel formulation with CsA Emulsion (formulation currently available on western markets) in the treatment of the above indication using different dosages and frequencies of administration, and to preliminarily determine the optimal conditions for the design of follow-up clinical study.

A total of 240 patients were enrolled in this study from 13 centers in China. The experimental drugs were given to three separate groups of subjects as follows: Treatment group A: CsA ophthalmic gel: 0.3 g: 0.15 mg, once daily; Treatment group B: CsA ophthalmic gel: 0.3 g: 0.15 mg, twice daily, with an interval of 12 hours; Treatment group C: CsA ophthalmic gel: 0.3 g: 0.3 mg, once daily. The positive control group received CsA Emulsion: 0.4 ml: 0.2 mg, twice daily, with an interval of 12 hours.

"Topline data of the current trial showed the new CsA Ophthalmic Gel formulation, (0.3 g: 0.15 mg, once daily) has similar or a trend towards better efficacy than the emulsion formulation currently on the western market," said Dr. Lit-Fui Lau, President of ZKO. "We believe that CsA Ophthalmic Gel is well positioned to address the unmet medical need in the treatment of patients with dry eye in China where ophthalmic CsA is still unavailable." "We have spent 10 years in the development of the patent-protected proprietary ophthalmic gel formulation of CsA. The topline data validated our commitment to the development of this innovative product," said Dr. Benjamin Li, Executive Director of COPFL.

ZKO plans to meet with the Center for Drug Evaluation in China to discuss and agree upon a Phase III protocol of the CsA Ophthalmic Gel trial. The pivotal study is expected to initiate patient recruitment in early 2020.

About Cyclosporine A Ophthalmic Gel

Cyclosporine A is a natural cyclic polypeptide immunosuppressant. It acts as a calcineurin inhibitor and suppresses T lymphocytes from releasing pro-inflammatory cytokines. The Cyclosporine A Ophthalmic Gel is a proprietary product shown to possess superior pharmacokinetics profile than that of the emulsion formulation in preclinical studies. It is under development for the treatment of keratoconjunctivitis sicca (dry eye) in China.

About China Ophthalmology Focus Ltd.

COPFL is an indirect non-wholly owned subsidiary of Lee's Pharmaceutical Holdings Limited (HKEx: 0950). Its Series A fund raising of USD 50 million in June 2019 was contributed by reputable investors including Coyote Investment Pte. Ltd., Panacea Venture Healthcare Fund I, L.P., Smart Rocket Ltd. and Vertex Profit International Ltd.. COPFL specializes in the development, manufacturing and marketing of ophthalmic drugs. It has built up a state-of-the-art development and production facility in Nansha, Guangzhou through its 100% subsidiary Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Limited. The facility supports the in-house development and future commercialisation of over 21 proprietary products and difficult to manufacture generics (ranged from pre-clinical to registration stage) for the Chinese and ASEAN markets. Its portfolio is diversified in having both small molecules and biologics, and having both novel and generic medicines, covering different ophthalmic indications from dry eye syndrome, glaucoma, wet Age-related Macular Degeneration (AMD), diabetic retinopathy to corneal and inflammatory diseases. It is currently the only modern facility in China that is recognised as being designed and built for ophthalmic drugs according to all applicable standards, namely China, Pharmaceutical Inspection Co-operation Scheme (PIC/S), EMEA, Japan and Food and Drug Administration (FDA).

Oct 31, 2019 11:10 HKT/SGT
Topic: Press release summary
Sectors: Daily Finance, HealthCare
From the Asia Corporate News Network

Copyright © 2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Latest Press Releases
New Disinfectant Stops Spread of Virus, Including Coronavirus Strain from China  
Jan 24, 2020 12:00 HKT/SGT
DOCOMO Releases White Paper Promoting 6G Communication System  
Jan 24, 2020 11:00 HKT/SGT
Fashion Hong Kong arrives at New York Fashion Week  
Jan 24, 2020 11:00 HKT/SGT
NEC Develops Millimeter-wave Distributed Antenna Radio Unit Improving the Channel Quality for Indoor 5G Applications  
Jan 24, 2020 10:05 HKT/SGT
Former New York University President John Sexton will be Asian University for Women's 2020 Commencement Speaker; an Indian economist, a Pakistani actress, and a Swiss educator will receive honorary degrees  
Jan 23, 2020 21:00 HKT/SGT
Garuda Indonesia Appoints Irfan Setiaputra as CEO  
Jan 23, 2020 19:00 HKT/SGT
Nissin Foods Forms Joint Venture Company to Strengthen Distribution Platform in PRC Market  
Jan 23, 2020 17:45 HKT/SGT
Eisai: Dayvigo (Lemborexant) Approved for Treatment of Insomnia in Japan  
Jan 23, 2020 14:57 HKT/SGT
Eisai: Approval of Antiepileptic Drug Fycompa in Japan for Monotherapy and Pediatric Indications for Partial-Onset Seizures, as well as a New Formulation  
Jan 23, 2020 14:46 HKT/SGT
Mitsubishi Corporation Participates in Vietnam's "Grand Park Project"  
Jan 23, 2020 11:39 HKT/SGT
More Press release >>
More >>
 News Alerts
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: